Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 9/20 | 0.54 |
| ▸ | DRD3 | P35462 | 8/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 3/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | C1S | P09871 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496702 | 1.00 | NOTUM (0.56) | NOTUMDRD2DRD3MAP4K1PRKCQ | |
| SCHEMBL21624920 | 0.91 | NOTUM (0.63) | NOTUMDRD2DRD3MAP4K1PRKCQ | |
| SCHEMBL21624919 | 0.91 | NOTUM (0.63) | NOTUMDRD2DRD3MAP4K1PRKCQ | |
| SCHEMBL7051829 | 0.82 | TRPC6 (0.52) | MAP4K1PRKCQLRRK2 | |
| SCHEMBL7471234 | 0.82 | TRPC6 (0.52) | MAP4K1PRKCQLRRK2 | |
| SCHEMBL3051168 | 0.82 | DRD2 (0.64) | NOTUMDRD2DRD3MAP4K1ALOX5 | |
| SCHEMBL29809089 | 0.80 | DRD2 (0.74) | NOTUMDRD2DRD3LRRK2ALOX5 | |
| SCHEMBL3537217 | 0.80 | DRD2 (0.74) | NOTUMDRD2DRD3LRRK2ALOX5 | |
| SCHEMBL28249062 | 0.80 | NOTUM (0.53) | NOTUMDRD2DRD3ALOX5 | |
| SCHEMBL4828838 | 0.79 | CHRNB2 (0.56) | MAP4K1PRKCQLRRK2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | NOTUM 4092/4885DRD2 796/4885DRD3 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.